S1P Therapeutics is a preclinical-stage biotechnology company focused on developing drugs targeting the sphingosine 1-phosphate (S1P) pathway. 

They are targeting SPNS2-dependent S1P transporters for the treatment of chronic kidney disease and other autoimmune diseases. Their studies to date reveal that their lead compound SPNS2 inhibitors are less broadly immunosuppressive and have less adverse events.